
Ajanta Pharma (AJANTPHARM) Share Price Rises 2.40% to Rs 3,363.20: Price Rise Analysis
Updated: 16 Nov 2026 • 1:32 pm
Posted by:

Ajanta Pharma Share Price is trading at Rs 3,363.20 as of 1:22 PM IST on 16 November 2026, up 2.40% from the previous close of Rs 3,284.40. The company has a market capitalisation of Rs 41,041.54 crore, and the Ajanta Pharma share price rise is the event behind this update.
Univest data confirms the move itself, though no company-specific trigger has been identified. This Ajanta Pharma stock analysis therefore sticks to what the numbers show: the intraday range, a P/E ratio of 32.50, a P/B ratio of 8.45, return on equity of 25.42% and return on capital employed of 32.67%.
Ajanta Pharma Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 3,363.2 |
| Previous Close | Rs 3,284.4 |
| Today's Move | Rs 78.8 (+2.4%) |
| Open | Rs 3,293.8 |
| High | Rs 3,402 |
| Low | Rs 3,284.4 |
| Market Capitalisation | Rs 41,041.54 crore |
| Market Cap Category | Large Cap |
Ajanta Pharma Ltd. (AJANTPHARM) rose to Rs 3,363.2 from the previous close of Rs 3,284.4, a move of Rs 78.8 or 2.4%. The stock opened at Rs 3,293.8, reached a high of Rs 3,402, recorded a low of Rs 3,284.4.
Ajanta Pharma Share Price Today stands at Rs 3,363.20, a gain of Rs 78.80 or 2.40% over the previous close of Rs 3,284.40. The stock opened at Rs 3,293.80 and has moved between Rs 3,284.40 and Rs 3,402.00 so far, as of 16 November 2026 at 1:22:47 PM IST.
The day open of Rs 3,293.80 was Rs 9.40 above the previous close. The day low of Rs 3,284.40 is exactly the previous close, so the Ajanta Pharma stock has not traded below its prior-session level at any point today. The day high of Rs 3,402.00 sits Rs 38.80 above the current price.
This Ajanta Pharma stock performance update also notes the company's market capitalisation of Rs 41,041.54 crore, which describes size and not quality. With the price action mapped, the next step is Ajanta Pharma fundamental analysis.
Ajanta Pharma Ltd. (AJANTPHARM) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 41,041.54 crore |
| P/E Ratio | 32.5x |
| P/B Ratio | 8.45x |
| ROE | 25.42% |
| ROCE | 32.67% |
| EPS | Rs 101.06 |
| Book Value Per Share | Rs 388.78 |
| Dividend Yield | 0.85% |
Ajanta Pharma Ltd. (AJANTPHARM) fundamental metrics show P/E 32.5x, P/B 8.45x, ROE 25.42%, ROCE 32.67%. Read together, these ratios describe the company's position rather than a recommendation.
Ajanta Pharma Ltd. has a market capitalisation of Rs 41,041.54 crore and falls in the Large Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 32.5x, P/B at 8.45x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 25.42% and ROCE of 32.67%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 101.06, book value per share of Rs 388.78, dividend yield of 0.85%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 30.93x, median ROE of 10.98%, median ROCE of 12.63%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 32.5x |
| Benchmark Median P/E | 30.93x |
| Benchmark Average P/E | 52.22x |
| Benchmark P/E Range | 2.6x to 1,177x |
| Company P/B Ratio | 8.45x |
| Benchmark Median P/B | 2.9x |
| Company ROE | 25.42% |
| Benchmark Median ROE | 10.98% |
| Company ROCE | 32.67% |
| Benchmark Median ROCE | 12.63% |
| Company Market Capitalisation | Rs 41,041.54 crore |
| Benchmark Median Market Cap | Rs 698.04 crore |
Ajanta Pharma Ltd. (AJANTPHARM) operates in the Healthcare sector, within the Pharmaceuticals & Drugs industry.
Ajanta Pharma Ltd. (AJANTPHARM) has a P/E ratio of 32.5x, which is above the benchmark median of 30.93x, a difference of +5.08%. The P/E comparison frames valuation; it is not a signal to buy or sell.
Ajanta Pharma Ltd. (AJANTPHARM) has a ROE of 25.42%, which is above the benchmark median of 10.98%, a difference of +131.51%. Ajanta Pharma Ltd. (AJANTPHARM) has a ROCE of 32.67%, which is above the benchmark median of 12.63%, a difference of +158.67%.
Track stocks leading today through the Univest top gainers screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | SUNPHARMA | 4,51,290.91 | 41.15 | 5.05 | 14.85 | 19.11 |
| Divi's Laboratories Ltd. | DIVISLAB | 3,05,014.11 | 90.7 | 16.95 | 16.19 | 21.51 |
| Torrent Pharmaceuticals Ltd. | TORNTPHARM | 1,77,333.2 | 83.49 | 9.65 | 26.76 | 19.27 |
| Laurus Labs Ltd. | LAURUSLABS | 1,30,755.56 | 97.59 | 21.57 | 18.31 | 18.2 |
| Zydus Lifesciences Ltd. | ZYDUSLIFE | 1,18,802.71 | 28.42 | 4.27 | 19.69 | 21.39 |
Ajanta Pharma Ltd. (AJANTPHARM) has a P/E ratio of 32.5x compared with the displayed peer median of 83.49x. Peer multiples give relative context only, not a buy or sell view. Its ROE of 25.42% compares with a peer median of 18.31% across the companies shown in the table. ROCE stood at 32.67% versus the displayed peer median of 19.27%, providing a capital-efficiency comparison. Ajanta Pharma Ltd. (AJANTPHARM) has a market capitalisation of Rs 41,041.54 crore. All 5 peers shown have a larger market capitalisation.
Why Investors Are Watching Ajanta Pharma
- Price action: Ajanta Pharma Share Price is up 2.40% at Rs 3,363.20 against a previous close of Rs 3,284.40.
- Intraday range: the stock has moved between Rs 3,284.40 and Rs 3,402.00 today.
- Returns: ROE of 25.42% and ROCE of 32.67% are above the industry medians of 10.98% and 12.63%.
- Valuation: a P/E ratio of 32.50 against an industry median of 30.93 and a P/B ratio of 8.45 against 2.90.
- Peer position: ROCE is the highest among the five listed peers shown in the comparison.
About Ajanta Pharma
Ajanta Pharma Ltd. trades under the symbol AJANTPHARM and is classified in the Healthcare sector under the Pharmaceuticals & Drugs industry. Its market capitalisation of Rs 41,041.54 crore places it well above the industry median of Rs 698.04 crore, and its ROE and ROCE are above the industry medians shown in the sector section.
For readers following Ajanta Pharma company news, the sector and peer sections above show how the business is positioned within a benchmark of 205 companies in the same industry.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Reg. No. INH000013776, a subsidiary of Univest Communication Technologies Private Limited).
Frequently Asked Questions
Why is Ajanta Pharma share price rising today?
Ans. Univest data confirms the move itself, though no company-specific trigger has been identified. Ajanta Pharma Share Price is at Rs 3,363.20, up 2.40% from the previous close of Rs 3,284.40, with a market capitalisation of Rs 41,041.54 crore.
What is the Ajanta Pharma share price today?
Ans. Ajanta Pharma Share Price was at Rs 3,363.20 as of 1:22:47 PM IST on 16 November 2026. That is a gain of Rs 78.80, or 2.40%, over the previous close of Rs 3,284.40, after an open at Rs 3,293.80.
What is the market capitalisation of Ajanta Pharma?
Ans. Ajanta Pharma has a market capitalisation of Rs 41,041.54 crore at the current Ajanta Pharma Share Price of Rs 3,363.20. The industry median is Rs 698.04 crore and the average is Rs 14,540.61 crore across the benchmark companies.
What are the day high and day low of Ajanta Pharma Share Price?
Ans. Ajanta Pharma Share Price has touched a high of Rs 3,402.00 and a low of Rs 3,284.40 today. The day low equals the previous close of Rs 3,284.40, and the stock now trades at Rs 3,363.20.
What is the P/E ratio of Ajanta Pharma?
Ans. The P/E ratio of Ajanta Pharma is 32.50, against an industry median of 30.93 and an industry average of 52.22. The P/B ratio is 8.45, compared with an industry median of 2.90 and an average of 3.43.
What are the ROE and ROCE of Ajanta Pharma?
Ans. Ajanta Pharma reports ROE of 25.42% and ROCE of 32.67%. The industry median ROE is 10.98% and the median ROCE is 12.63%, so both returns are above the benchmark medians at the current Ajanta Pharma Share Price.
What are the EPS and book value of Ajanta Pharma?
Ans. Ajanta Pharma has an EPS of Rs 101.06 and a book value of Rs 388.78 per share. EPS shows earnings per share, while book value shows the accounting net worth behind each share, next to the Ajanta Pharma Share Price of Rs 3,363.20.
What is the dividend yield of Ajanta Pharma?
Ans. The dividend yield of Ajanta Pharma is 0.85%. It reflects the historical payout relative to the current price of Rs 3,363.20 and says nothing certain about future payouts, so it is one input in the wider Ajanta Pharma fundamental analysis.
Track Ajanta Pharma Share Price on Univest
Use Ajanta Pharma Ltd. (AJANTPHARM) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top-gainers lists and related market analysis.
Users can track the live Ajanta Pharma Share Price on Univest, along with fundamental ratios, 52-week levels and market insights for the stock. Univest brings the price, the valuation multiples and the sector benchmark together so that the Ajanta Pharma stock update can be followed in one place as the session continues.
Recent Articles

Cummins India Share Price Slips to Rs 4,005 Near Its 52-Week Low: Margins Squeezed by Commodity Costs While Price Hikes Take a Quarter to Flow Through
18 November 2026

V2 Retail Share Price Plunges 15% to a 52-Week Low of Rs 122.73 Then Rebounds to Close at Rs 141.61: What We Know, What We Do Not and the Numbers to Watch
18 November 2026

Infosys Share Price Falls to Rs 1,108.80, Down 25.4% in a Year: How India's IT Bellwether Lost a Quarter of Its Value and What Investors Should Check Next
18 November 2026

Nifty Bank 62,000: Index Closes at 62,038.65 After a Record 62,442.20, Up 24% From Its April Low as SBI Surges While HDFC Bank and Axis Bank Lag
18 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Cummins India Share Price Slips to Rs 4,005 Near Its 52-Week Low: Margins Squeezed by Commodity Costs While Price Hikes Take a Quarter to Flow Through
V2 Retail Share Price Plunges 15% to a 52-Week Low of Rs 122.73 Then Rebounds to Close at Rs 141.61: What We Know, What We Do Not and the Numbers to Watch
Infosys Share Price Falls to Rs 1,108.80, Down 25.4% in a Year: How India's IT Bellwether Lost a Quarter of Its Value and What Investors Should Check Next
Nifty Bank 62,000: Index Closes at 62,038.65 After a Record 62,442.20, Up 24% From Its April Low as SBI Surges While HDFC Bank and Axis Bank Lag
Mahanadi Coalfields IPO Opens 19 November: Rs 129 to Rs 136 Price Band, Rs 8,981 Crore Offer for Sale and a Coal India Unit Valued at About 8.4 Times Earnings

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





